Insights and news
Stephenson Harwood advises Shield Therapeutics plc on exclusive Japan licence
Law firm Stephenson Harwood LLP has advised Shield Therapeutics plc on its exclusive licence agreement with VITAL-NET, Inc. for ACCRUFeR® in Japan.
Stephenson Harwood advises Bicycle Therapeutics on radiotherapy deal with Bayer
Law firm Stephenson Harwood LLP has advised Bicycle Therapeutics plc on its recent strategic collaboration agreement with Bayer to discover and develop Bicycle radioconjugates for multiple oncology targets.
Stephenson Harwood advises Bicycle Therapeutics on radiopharmaceuticals deal with Novartis
Law firm Stephenson Harwood LLP has advised Bicycle Therapeutics on its recent strategic collaboration agreement with Novartis to discover and develop multiple targeted radioligand therapies in oncology.
Stephenson Harwood advises Oxford Biomedica on new AstraZeneca agreement
Law firm Stephenson Harwood LLP has advised Oxford Biomedica, the gene and cell therapy company, on its new three year Master Services & Development Agreement with AstraZeneca UK Ltd (AstraZeneca), which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine.
